A
NGNE icon

AlphaQuest’s Neurogene NGNE Stock Holding History

AlphaQuest’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-7,215
Closed -$149K – 1333
2025
Q4 		$149K Sell
7,215
-9,239
-56% -$230K 0.01% 1579
2025
Q3 		$285K Buy
16,454
+11,335
+221% +$228K 0.02% 1191
2025
Q2 		$76.5K Sell
5,119
-1,490
-23% -$23.4K 0.01% 1512
2025
Q1 		$77.4K Buy
+6,609
New +$115K 0.01% 1397
2024
Q4 		– Sell
-1,279
Closed -$53.7K – 1915
2024
Q3 		$53.7K Sell
1,279
-244
-16% -$9.46K ﹤0.01% 1400
2024
Q2 		$55.4K Buy
+1,523
New +$53.7K 0.01% 1057

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

AlphaQuest's NGNE Position: Q1 2026 in Review

AlphaQuest sold out of Neurogene (NGNE) in Q1 2026, closing a stake of 7,215 shares — an estimated $149K sold.

AlphaQuest first reported a position in NGNE in Q2 2024 and held it in 6 quarters. The position peaked at $285K in Q3 2025. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

  • AlphaQuest reported no remaining Neurogene position as of Q1 2026 after selling out during the quarter.
  • AlphaQuest sold 7,215 Neurogene shares in Q1 2026, an estimated $149K.
  • AlphaQuest first reported a position in Neurogene in Q2 2024 and held it in 6 quarters.
  • AlphaQuest's Neurogene position peaked at $285K in Q3 2025.
  • 96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.